TABLE 2.
Results of PD-L1 immunohistochemistry.
| Case no | Diagnosis | Epidermis | Dermis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KC PD-L1 (%) | CD3 (count/field) | CD4 (count/field) | CD8 (count/field) | GB (count/field) | GB/CD8 ratio | PD-1 (count/field) | PD-1/CD3 ratio | PD-L1 (count/field) | CD123 | CD163 | ||
| 1 | DI-SCLE | 40 | 360 | 160 | 120 | 25 | 0.21 | 12 | 0.03 | 65 | 2+ | 2+ |
| 2 | DI-SCLE | 50 | 80 | 18 | 66 | 13 | 0.20 | 8 | 0.10 | 68 | 1+ | 3+ |
| 3 | I-SCLE | 80 | 280 | 102 | 230 | 54 | 0.23 | 48 | 0.17 | 105 | 2+ | 1+ |
| 4 | I-SCLE | 80 | 145 | 20 | 78 | 41 | 0.53 | 12 | 0.08 | 28 | 3+ | 2+ |
| SCLE group median | 65 | 212.5 | 61 | 99 | 33 | 0.22 | 12 | 0.09 | 66.5 | |||
| 5 | DLE | 5 | 260 | 190 | 78 | 48 | 0.62 | 55 | 0.21 | 38 | 1+ | 2+ |
| 6 | DLE | 5 | 400 | 235 | 140 | 68 | 0.49 | 21 | 0.05 | 90 | 3+ | 2+ |
| 7 | DLE | 5 | 110 | 10 | 90 | 35 | 0.39 | 20 | 0.18 | 22 | 2+ | 1+ |
| 8 | DLE | 30 | 230 | 40 | 180 | 79 | 0.44 | 40 | 0.17 | 90 | 3+ | 2+ |
| DLE group median | 5 | 245 | 115 | 115 | 58 | 0.46 | 30.5 | 0.18 | 64 | |||
| 9 | TEN-like lupus (early) | 30 | 138 | 18 | 87 | 22 | 0.24 | 45 | 0.12 | 68 | — | 3+ |
| 10 | TEN-like lupus (late) | 70 | 108 | 26 | 90 | 43 | 0.49 | 27 | 0.20 | 13 | — | 3+ |
KC PD-L1 stainings were evaluated in the whole sample and were considered positive if there was moderate to high intensity staining in >1% of the cells (SCLE, subacute cutaneous lupus erythematosus; DI-SCLE, PD-1 inhibitor-induced SCLE; DLE, discoid lupus erythematosus; TEN, toxic epidermal necrolysis; KC, keratinocyte; PD-L1, programmed cell death ligand 1).